Baker Brothers sells 322,039 TARA shares; additional broker placements listed (TARA)

Rhea-AI Filing Summary

TARA: A Form 144 filing reports planned or completed dispositions of Common Stock by selling holders. The filing shows a sale of 322,039 shares by Baker Brothers Life Sciences, L.P. on 02/24/2026. It also lists proposed methods and additional sale quantities including 24,186 shares (underwriter) dated 12/08/2025 and 923,293 shares (broker) dated 02/25/2026.

The filing lists intermediaries such as Canaccord Genuity LLC and identifies NASDAQ as the exchange. These entries indicate registered resale activity by institutional holders rather than corporate actions by the issuer.

Insights

Equity Markets Analyst

Large institutional resale activity reported, comprised mainly of a 322,039-share completed sale and larger planned broker/underwriter placements.

The excerpt shows a completed disposition of 322,039 shares by Baker Brothers Life Sciences, L.P. on 02/24/2026, plus listed planned sales of 24,186 shares via an underwriter (12/08/2025) and 923,293 shares via broker methods (02/25/2026).

These entries represent selling‑holder transactions and not an issuer issuance; cash‑flow treatment is not specified in the provided excerpt. Subsequent transaction notices or exchange records will show actual execution and timing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Canaccord Genuity LLC 99 High Street Suite 1200 Boston MA 02110	947479	5501316.00	53587260	02/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	12/08/2025	See Remark 2	Underwriter			24186	12/08/2025	Cash
Common Stock	02/25/2026	See Remark 3	Broker			923293	02/25/2026	See Remark 3

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Baker Brothers Life Sciences, L.P. 860 Washington Street 3rd Floor New York NY 10014	Common Stock	02/24/2026	322039	1944922.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TARA Form 144 filing report?

It reports dispositions of Common Stock, including a sale of 322,039 shares by Baker Brothers Life Sciences on 02/24/2026. The filing also lists planned sales of 24,186 and 923,293 shares with intermediary methods noted.

Who sold shares in the TARA Form 144 filing?

The filing identifies Baker Brothers Life Sciences, L.P. as a seller of 322,039 shares on 02/24/2026. Other sale quantities are listed with intermediaries such as Canaccord Genuity LLC as broker/underwriter.

What sale methods are listed in the TARA filing?

The excerpt lists sale methods including underwriter and broker transactions, with specific entries of 24,186 shares (underwriter) and 923,293 shares (broker) tied to dated entries in the filing.

Does the Form 144 indicate issuer dilution for TARA?

No—this filing documents selling‑holder transactions in Common Stock, not new issuances by the company. The entries reflect resale activity by holders rather than shares issued by the issuer.

Where was the TARA stock listed for these transactions?

The filing lists NASDAQ as the exchange. Intermediaries named include Canaccord Genuity LLC with address details shown in the excerpt for broker/dealer handling.